New lupus kidney trial aims to ditch steroids without sacrificing control
NCT ID NCT04702256
First seen Dec 12, 2025 · Last updated Jun 04, 2026 · Updated 22 times
Summary
This study tests whether a new drug combination (obinutuzumab plus mycophenolate mofetil) can control lupus-related kidney inflammation without the need for oral steroids. About 196 people with active lupus nephritis will be randomly assigned to either the standard steroid-based regimen or the steroid-free approach. The goal is to see if the steroid-free option works just as well while avoiding the serious side effects of long-term steroid use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Internal medicine, Cochin hospital, APHP
RECRUITINGParis, 75014, France
Contact
Conditions
Explore the condition pages connected to this study.